title: Analysis of the mechanisms underlying the vasorelaxant action of coptisine in rat aortic rings.
abstract: The aim of the present study was to evaluate the vasorelaxant effects of coptisine and its possible mechanisms in isolated rat aortic rings. Coptisine was evaluated on isolated rat aortic rings precontracted with norepinephrine (NE) and KCl. The mechanisms were evaluated in the presence or absence of specific pharmacological inhibitors. Coptisine (1 ~ 200 μM) relaxed NE (1 μM) or KCl (60 mM) induced sustained contraction with pEC(50) values of 4.49 ± 0.48 and 4.85 ± 0.57 in a concentration dependent manner. Pretreatment with coptisine (10, 50 or 100 μM) also inhibited concentration-response curves to NE and KCl. The vasorelaxant effect of coptisine was attenuated significantly by endothelium removal, and incubation with Nω-nitro-L-arginine methyl ester (L-NAME, 100 μM), methylene blue (10 μM) and indomethacin (5 μM) partially reduced the vasorelaxant effect of coptisine. In endothelium-denuded rings, the vasorelaxant effect of coptisine was reduced significantly by 4-aminopyridine (4-AP, 100 μM), but not glibenclamide (10 μM) ortetraethylammonium (TEA, 5 mM). Coptisine also reduced NE-induced transient contraction in Ca(2+)-free solution, and inhibited contraction induced by increasing external calcium in Ca(2+)-free medium plus 60 mM KCl. It was concluded that coptisine induced both endothelium-dependent and -independent relaxation in rat aortic rings. The NO-cGMP mediated pathway may be involved in the endothelium-dependent relaxation and in the activation of voltage-dependent K(+) channels, contributing in part to the endothelium-independent relaxation bycoptisine. Coptisine also blocks extracellular Ca(2+) influx by interacting with both voltage- and receptor-operated Ca(2+) channels.
authors.affiliation: Beijing Key Laboratory of Drug Targets Identification and Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Gong
authors.forename: Lian-Hua
authors.initials: LH
authors.lastname: Fang
authors.forename: Hai-Lin
authors.initials: HL
authors.lastname: Qin
authors.forename: Yang
authors.initials: Y
authors.lastname: Lv
authors.forename: Guan-Hua
authors.initials: GH
authors.lastname: Du
mesh_terms: D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects*; D001599:Berberine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D039323:Coptis / Q000737:chemistry*; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D004365:Drugs, Chinese Herbal; D014665:Vasodilator Agents; C034384:coptisine; D001599:Berberine; D002118:Calcium